EHA Expert Interview | Professor Lihua Qiu from Professor Huilai Zhang’s Team Unveils PGI-FL, MCL Research Advances, and New Mechanisms of CD58

EHA Expert Interview | Professor Lihua Qiu from Professor Huilai Zhang’s Team Unveils PGI-FL, MCL Research Advances, and New Mechanisms of CD58

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts numerous renowned experts and scholars each year to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. At this year's meeting, several research findings from Professor Huilai Zhang's team at Tianjin Medical University Cancer Institute & Hospital were selected. To gain a deeper understanding of the latest research progress in the field of lymphoma, "Oncology Frontier - Hematology Frontier" has invited Professor Lihua Qiu from the same team for an in-depth interpretation.
EHA China Voice | Professor Li Wang’s Team: Two Studies on DLBCL MRD Monitoring and Orelabrutinib in iNHL Treatment Featured at EHA

EHA China Voice | Professor Li Wang’s Team: Two Studies on DLBCL MRD Monitoring and Orelabrutinib in iNHL Treatment Featured at EHA

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world each year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's EHA conference, two studies by Professor Li Wang's team from Ruijin Hospital, Shanghai JiaoTong University School of Medicine (abstracts P1716 and 2074), explored minimal residual disease (MRD) monitoring in diffuse large B-cell lymphoma (DLBCL) and the application of the new BTK inhibitor orelabrutinib in the treatment of indolent non-Hodgkin lymphoma (iNHL). Oncology Frontier - Hematology Frontier specially translated and organized the content of these two studies for readers' reference.
Expert Viewpoint: Professor Jun Li on Comprehensive Management of HBV Reactivation Related to Antitumor Treatment

Expert Viewpoint: Professor Jun Li on Comprehensive Management of HBV Reactivation Related to Antitumor Treatment

In a study conducted by Metzler F et al. from 2005-2007, involving 258 patients who received one course of Rituximab treatment, 46% had received the hepatitis B vaccine, 11% were Anti-HBc/anti-HBs positive, and less than 1% were HBV DNA positive. The study found that the average Anti-HBs level in vaccinated individuals dropped significantly from 80 IU/mL to 38 IU/mL (P<0.05) after Rituximab treatment. Among three patients with inactive HBV infection, HBV DNA became detectable, and ALT levels increased post-treatment. With the increasing use of antitumor drugs in recent years, HBV reactivation and hepatitis B flare-ups have become significant clinical concerns. We have invited Professor Jun Li from the First Affiliated Hospital of Nanjing Medical University to discuss the comprehensive management of HBV reactivation related to antitumor treatment for the benefit of our peers.
ISTH Academician’s Voice | Academician Heyu Ni: Global Chinese Scientists Leading New Directions in Thrombosis Research

ISTH Academician’s Voice | Academician Heyu Ni: Global Chinese Scientists Leading New Directions in Thrombosis Research

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand. As the most influential international event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world with its profound academic impact and rich content. At this grand event, "Oncology Frontier - Hematology Frontier" had the honor of interviewing Academician Heyu Ni of the Canadian Academy of Health Sciences, who also serves as the chairman of the Joint ISTH Conference of Global Chinese Thrombosis and Hemostasis. In the interview, Academician Ni shared his extensive academic background and unique insights, offering us valuable academic reflections and insights. Here is the interview in text form for our readers.
Asciminib (ASC) as First-Line Treatment for Newly Diagnosed CML Shows Superior Efficacy, Safety, and Tolerability Compared to Current TKIs

Asciminib (ASC) as First-Line Treatment for Newly Diagnosed CML Shows Superior Efficacy, Safety, and Tolerability Compared to Current TKIs

Chronic myeloid leukemia (CML) requires long-term treatment, emphasizing the importance of both efficacy and long-term safety and tolerability to achieve treatment goals, including treatment-free remission (TFR). Asciminib (ASC) is the first specific inhibitor targeting the ABL myristoyl pocket (STAMP) of BCR:ABL1, offering high specificity and minimal off-target effects. From June 13-16, 2024, the 29th Annual Meeting of the European Hematology Association (EHA) was held in Madrid, Spain. At the conference, an international multicenter phase III randomized controlled study, ASC4FIRST (NCT04971226), compared the efficacy and safety of ASC with standard first-line TKIs for newly diagnosed CML patients. The results demonstrated that ASC as a first-line treatment for newly diagnosed CML has superior efficacy, safety, and tolerability compared to current TKIs. We have invited Professor Bingcheng Liu from the Leukemia Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , to review this study.
Zanubrutinib Combined with R-Chemo Shows Significant Efficacy and Good Safety as First-Line Treatment for Newly Diagnosed Mantle Cell Lymphoma

Zanubrutinib Combined with R-Chemo Shows Significant Efficacy and Good Safety as First-Line Treatment for Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, a common malignant tumor of the hematological system, has always been a focus of research for innovative and optimized treatment strategies. In recent years, with the rise of immunotherapy and targeted therapy, lymphoma treatment strategies are undergoing revolutionary changes. The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. With the rapid development of hematology, Chinese research teams also showcased many innovative treatment plans and clinical research results at this year's EHA conference. At this meeting, Professor Haiwen Huang from The First Affiliated Hospital of Soochow University announced the results of a study on zanubrutinib combined with rituximab and chemotherapy (ZR-chemo) for the treatment of newly diagnosed mantle cell lymphoma. "Oncology Frontier - Hematology Frontier" invited Professor Haiwen Huang to share and interpret the findings of this study.
Renowned Interview | Professor R. Andrade: Drug-induced Autoimmune Hepatitis – A Challenging New Phenotype

Renowned Interview | Professor R. Andrade: Drug-induced Autoimmune Hepatitis – A Challenging New Phenotype

Drug-induced autoimmune hepatitis, as a new and complex disease phenotype, has received widespread attention in recent years. On May 25, 2024, at the "8th International Forum on Drug-induced Liver Injury" in Malaga, Spain, Professor Raul J. Andrade of the Malaga Biomedical Research Center at the University of Malaga delivered a fascinating lecture on drug-induced autoimmune hepatitis. Our journal had the privilege of conducting an exclusive interview with Professor Andrade, delving into the specific characteristics of the disease, diagnostic challenges, treatment strategies, and future research directions. We have organized the content into an article, hoping to enhance clinicians' understanding of the disease, optimize patient treatment outcomes, and improve quality of life.
EHA in 5 Minutes | Professor Huanling Zhu: PONAZA Trial— Ponatinib and Azacitidine for Treating Myeloid Blast Crisis in CML (NCT03895671)

EHA in 5 Minutes | Professor Huanling Zhu: PONAZA Trial— Ponatinib and Azacitidine for Treating Myeloid Blast Crisis in CML (NCT03895671)

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. To gain a deeper understanding of the latest research in Chronic Myeloid Leukemia (CML), "Oncology Frontier - Hematology Frontier" has invited Professor Huanling Zhu from West China Hospital of Sichuan University, to provide an in-depth interpretation.
Chinese CAR-T Cell Therapy Phase 1 Study Shows Promise for HIV Functional Cure

Chinese CAR-T Cell Therapy Phase 1 Study Shows Promise for HIV Functional Cure

In a pioneering clinical trial, a novel multifunctional CAR-T cell treatment has demonstrated remarkable efficacy and safety in HIV-1 infected patients, potentially paving the way for a functional cure for HIV/AIDS. Published in Cell Discovery, the phase I study introduced M10 CAR-T cells, engineered to incorporate endogenous broadly neutralizing antibodies (bNAbs) and the follicle-homing receptor CXCR5.